PubRank

Andrew Zalewski

Author PubWeight™ 37.22‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Human epicardial adipose tissue is a source of inflammatory mediators. Circulation 2003 6.31
2 Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS). Am Heart J 2011 3.93
3 Inhibition of lipoprotein-associated phospholipase A2 reduces complex coronary atherosclerotic plaque development. Nat Med 2008 3.33
4 Effects of the direct lipoprotein-associated phospholipase A(2) inhibitor darapladib on human coronary atherosclerotic plaque. Circulation 2008 2.62
5 The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized, double-blind, placebo-controlled study. J Am Coll Cardiol 2008 2.41
6 The ATHEROMA (Atorvastatin Therapy: Effects on Reduction of Macrophage Activity) Study. Evaluation using ultrasmall superparamagnetic iron oxide-enhanced magnetic resonance imaging in carotid disease. J Am Coll Cardiol 2009 1.76
7 Diabetes-induced oxidative stress and low-grade inflammation in porcine coronary arteries. Circulation 2003 1.65
8 Rationale and methods of the integrated biomarker and imaging study (IBIS): combining invasive and non-invasive imaging with biomarkers to detect subclinical atherosclerosis and assess coronary lesion biology. Int J Cardiovasc Imaging 2005 1.42
9 Role of lipoprotein-associated phospholipase A2 in leukocyte activation and inflammatory responses. Atherosclerosis 2006 1.34
10 Lipoprotein-associated phospholipase A2 as a target of therapy. Curr Opin Lipidol 2005 1.27
11 Site-specific atherogenic gene expression correlates with subsequent variable lesion development in coronary and peripheral vasculature. Arterioscler Thromb Vasc Biol 2008 1.21
12 Diverse origin of intimal cells: smooth muscle cells, myofibroblasts, fibroblasts, and beyond? Circ Res 2002 1.19
13 Noninvasive detection of subclinical coronary atherosclerosis coupled with assessment of changes in plaque characteristics using novel invasive imaging modalities: the Integrated Biomarker and Imaging Study (IBIS). J Am Coll Cardiol 2006 1.08
14 Clinical outcome endpoints in heart failure trials: a European Society of Cardiology Heart Failure Association consensus document. Eur J Heart Fail 2013 1.04
15 Site selection in global clinical trials in patients hospitalized for heart failure: perceived problems and potential solutions. Heart Fail Rev 2014 1.03
16 Role of lipoprotein-associated phospholipase A2 in atherosclerosis and its potential as a therapeutic target. Curr Opin Pharmacol 2006 0.97
17 Interaction between baseline and early worsening of renal function and efficacy of renin-angiotensin-aldosterone system blockade in patients with heart failure: insights from the Val-HeFT study. Eur J Heart Fail 2013 0.86
18 Lipoprotein-associated phospholipase A2: a novel marker of cardiovascular risk and potential therapeutic target. Expert Opin Investig Drugs 2005 0.85
19 Assessment on the Prevention of Progression by Rosiglitazone on Atherosclerosis in diabetes patients with Cardiovascular History (APPROACH): study design and baseline characteristics. Am Heart J 2008 0.82
20 The future of clinical trials in secondary prevention after acute coronary syndromes. Eur Heart J 2010 0.81
21 Peripheral artery disease, biomarkers, and darapladib. Am Heart J 2011 0.79
22 Differential protein biomarker expression and their time-course in patients with a spectrum of stable and unstable coronary syndromes in the Integrated Biomarker and Imaging Study-1 (IBIS-1). Int J Cardiol 2010 0.76
23 Standardization of outcome measures in clinical trials of pharmacological treatment for abdominal aortic aneurysm. Expert Rev Cardiovasc Ther 2012 0.76
24 First-in-man prospective evaluation of temporal changes in coronary plaque composition by in vivo intravascular ultrasound radiofrequency data analysis: an Integrated Biomarker and Imaging Study (IBIS) substudy. EuroIntervention 2005 0.75
25 Clinical trials in hospitalized heart failure patients: targeting interventions to optimal phenotypic subpopulations. Heart Fail Rev 2015 0.75